Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 262-967-7 | CAS number: 61788-32-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP-compliant study, available as unpublished report, well-documented, no restrictions, adequate for assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Terphenyl, hydrogenated
- EC Number:
- 262-967-7
- EC Name:
- Terphenyl, hydrogenated
- Cas Number:
- 61788-32-7
- Molecular formula:
- C18Hn (n >18-36)
- IUPAC Name:
- Terphenyl, hydrogenated
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc., Wilmington, Massachusetts 01887
- Age at study initiation: 9 weeks (males) and 8 weeks (females)
- Weight at study initiation: 319 gr for males (300-339) and 192 gr for females (175-208)
- Housing: doubly housed during the first week then individually housed
- Diet (e.g. ad libitum): ad libitum (Standard laboratory diet) during acclimation period; None during exposure period
- Water (e.g. ad libitum): ad libitum during acclimation period; None during exposure period
- Acclimation period: 21/22 days (4 to 25/26 September 1984)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-31 °C
- Humidity (%): 24-95% (R.H.)
- Photoperiod (hrs dark / hrs light): 12 hour light/dark cycle (7am to 7 pm)
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Remarks on MMAD:
- MMAD / GSD: Batelle cascade impactor:
MMAD (microns): 1.9, 1.8, 1.6 for groups exposed to 10, 100 ang 500 mg/m³ respectively.
GSD: 2.0, 1.8, 1.9 for groups exposed to 10, 100 ang 500 mg/m³ respectively.
TSI model:
MMAD (microns): 3.1, 2.0, 4.7 for groups exposed to 10, 100 ang 500 mg/m³ respectively.
GSD: 1.9, 1.9, 2.8 for groups exposed to 10, 100 ang 500 mg/m³ respectively. - Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Chamber volume: one cubic meter
- Effective volume: 760 liters
- Air flow rate: average of 200 liters per minute (1 ppm)
- Air change rate: one complete air change every 5 minutes (average)
- Method of particle size determination: Using a Batelle cascade impactor and a TSI model 3300/3302 Aerodynamic Particle Sizer. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Exposure levels were determined by gas chromatographic assay (GC) of samples collected on filters. Concentration was also monitored gravimetrically as a secondary assay. In addition, distribution samples were taken at least three times during the study from four locations in the chamber for each group and assayed by GC.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- 6 hours/day, 5 days/week (67 number of exposures per group/sex)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/m³ air
- Dose / conc.:
- 10 mg/m³ air
- Remarks:
- corresponding to 11.4 mg/m³ (males) and 11.3 mg/m³ (females)
- Dose / conc.:
- 100 mg/m³ air
- Remarks:
- corresponding to 98.7 mg/m³ (males) and 98.4 mg/m³ (females)
- Dose / conc.:
- 500 mg/m³ air
- Remarks:
- corresponding to 480 mg/m³ (males) and 479 mg/m³ (females)
- No. of animals per sex per dose:
- 15 animals per sex per group
- Control animals:
- yes
Examinations
- Observations and examinations performed and frequency:
- MORTALITY AND GROSS SIGNS OF TOXICOLOGIC OR PHARMACOLOGIC EFFECT:
- Time schedule: twice daily
DETAILED PHYSICAL OBSERVATIONS: Yes
- Time schedule: once a week
BODY WEIGHT: Yes
- Time schedule for examinations: Recorded pretest, weekly during the study and at termination.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: pretest and at termination
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at midterm and after the sixty-fifth exposure (males) and sixty-fourth exposure (females)
- Anaesthetic used for blood collection: Yes (identity): light ether anesthesia.
- Animals fasted: Yes
- How many animals: 40 animals (10/sex/group)
- Parameters checked in Table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at midterm and after the sixty-fifth exposure (males) and sixty-fourth exposure (females)
- Animals fasted: Yes
- How many animals: 40 animals (10/sex/group)
- Parameters checked in Table 2 were examined. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see Table 3)
HISTOPATHOLOGY: Yes (see Table 4)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
One Group I (control) female and one Group II (10 mg/m³) female died spontaneously during the study. Two Group II females and one Group IV (500 mg/m³) female died accidentally during blood collection. The one Group II female's spontaneous death did not appear to be treatment related.
Increased incidences of chromodacryorrhea, excess lacrimation and rough coat were exhibited by all groups of treated males compared to control males. The increased incidence of rough coat noted in the treated males did not appear to correlate with the presence of test material on the fur. Increased incidences of dried brown material around the facial area were exhibited by all treated groups of females compared to control females. These findings were considered to be treatment related.
BODY WEIGHT AND WEIGHT GAIN:
The mean body weights were decreased approximately 8% for the Group IV males during the study compared to the control males. The differences between Group IV and control males were considered suggestive of a treatment related effect. Comparisons between body weights for Group II and III (100 mg/m³) males and all groups of treated females, and the respective control animals were considered unremarkable.
OPHTHALMOSCOPIC EXAMINATION:
The following findings were noted at the terminal ophthalmology examination: proptosis and corneal necrosis (unilateral, 1 Group II male), conjunctivitis secondary to infectious disease or dental abnormality (unilateral, 1 Group IV male), retinal degeneration (bilateral, 1 Group I female) and phthisis bulbi which was secondary trauma or endophthalmitis (unilateral, 1 Group I female and 1 Group III female). These findings were not considered treatment related.
HAEMATOLOGY:
Haematology results were considered unremarkable.
CLINICAL CHEMISTRY:
The mean serum glutamic oxaloacetic transaminase and glucose levels were decreased for the Group IV females compared to the control females, and the mean total protein, albumin and calcium levels were increased for Group III and IV females compared to control females. Because the findings followed a pattern related to exposure concentration for Group III and IV females, these differences appeared to be treatment related. However, the majority of values were within historical control ranges and the nature of changes is not suggestive of an adverse effect. The absence of supporting microscopic lesions or organ weight findings in the liver, heart or other tissues suggests these clinical chemistry differences were insufficient to be considered toxicologically significant.
The mean blood urea nitrogen level was increased for Group IV males at Test Week 14 compared to control males. However, values were within historical ranges and no renal pathology was seen. Therefore, this difference is not considered to be toxicologically significant.
ORGAN WEIGHTS:
The mean absolute and relative liver weights were increased for all groups of treated males compared to control males. The differences between treated and control males were statistically significant for all comparisons except for the absolute liver weights of Group II and III males. These findings were considered treatment related. Mean absolute and relative liver weights were unremarkable in the treated females. There were no other findings in the organ weight data of the males or females which were attributed to the test material.
GROSS PATHOLOGY & HISTOPATHOLOGY (NON-NEOPLASTIC)
Postmortem findings, observed grossly and microscopically, either occurred in the treated and control animals with comparable incidence and severity or they occurred sporadically. These findings did not appear to be related to the test article.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 0.1 mg/L air
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- gross pathology
- haematology
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
- Dose descriptor:
- LOAEL
- Effect level:
- 0.5 mg/L air
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- gross pathology
- haematology
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
1) 0.01 mg/L
liver, weight, incr, M;
lacrimation, M;
chromodacryorrhea, M;
Dried brown material around the facial area,
F.
2) 0.1 mg/L
Liver, weight, incr, M;
Lacrimation, M;
Chromodacryorrhea, M;
Dried brown material around the facial area, F;
NOAEL.
3) 0.5 mg/L
Liver, weight, incr, M;
Body weight, decr, M;
Lacrimation, M;
Chromodacryorrhea, M;
Dried brown material around the facial area, F;
LOAEL.
Applicant's summary and conclusion
- Conclusions:
- NOAEL = 100 mg/m³ or 0.1 mg/L air.
- Executive summary:
Terphenyl, hydrogenated when administered by whole-body inhalation exposure as an aerosol to 90 CD (Sprague-Dawley derived) rats (15/sex/group) for six hours per day, five days per week for thirteen weeks at target concentrations of 0, 10, 100 and 500 mg /m³ (groups I, II, III,IV). Exposure levels for Groups I-IV were determined by gas chromatographic assay (GC) of samples collected on filters. Concentration was also monitored gravimetrically for Groups II, III and IV as a secondary assay. In addition, distribution samples were taken at least three times during the study from four locations in the chamber for each group (Groups II-IV) and assayed by GC. Particle size distribution measurements were made using a Batelle cascade impactor and a TSI Model 3300/3302 Aerodynamic Particle Sizer. Detailed physical examinations were conducted once a week on all animals; in addition, once per exposure the animals were observed as a group in-chamber. Body weights were recorded pretest, weekly during the study and at termination. Blood specimens for hematology and clinical chemistry evaluations were collected from 40 animals (10/sex/group) at midterm and from the same 10 animals/sex/group after the sixty-fifth exposure(males) and sixty-fourth exposure (females). All animals (Groups I-IV) were weighed prior to sacrifice. Complete gross postmortem examinations were conducted on all animals ; selected organs were weighed and organ/body weight ratios were calculated. Histopathological evaluations were performed on selected tissues from all animals of the control and high-dose groups ( Groups I and IV). The tissues and organs with visible lesions, and masses from all animals were examined microscopically. The treated animals were exposed to cumulative mean analytical concentrations of 11, 99/98 (Male/Female) and 480 mg/m³ Terphenyl, hydrogenated, respectively. Particle size distribution measurements revealed the test atmospheres contained particles of respirable size. One Group I female and one Group II female died spontaneously during the study. The Group II female’s death was not considered treatment related. Increased incidences of chromodacryorrhea, excess lacrimation and rough coat were exhibited by all groups of treated males compared to control males. Increased incidences of dried brown material around the facial area were exhibited by all treated groups of females compared to control females. These findings were considered to be treatment related. The mean body weights were decreased approximately 8% for the Group IV males during the study compared to the control males. The differences between Group IV and control males were considered suggestive of a treatment related effect. Although some statistically significant differences were seen at study termination between clinical chemistry values for control and treated groups, values were generally within control ranges and the absence of supporting microscopic lesions or organ weight findings suggests these clinical chemistry results were insufficient to be considered toxicologically significant. The mean absolute and relative liver weights were increased for all groups of treated males compared to control males. The differences between treated and control males were statistically significant for all comparisons except for the absolute liver weights of Group II and III males. Postmortem findings, observed grossly and microscopically, either occurred in the treated and control animals with comparable incidence and severity or they occurred sporadically. These findings did not appear to be related to the test article. The NOAEL was considered to be 100 mg/m³ or 0.1 mg/L air.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)